Gaxin Xia
September 14, 2021 07:05 AM EDTUpdated September 16, 11:40 AM
Financing

Shang­hai biotech tack­ling kid­ney dis­ease gets an­oth­er round of cash

Max Gelman

Senior Editor

Four months af­ter a se­cre­tive Shang­hai biotech pulled in $60 mil­lion for a Se­ries B round, it’s re­turn­ing to the fore with a lit­tle more …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Bris­tol My­ers re­veals more job cuts in New Jer­sey

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta 

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

A service from the Financial Times